(Alliance News) - Oncimmune Holdings PLC said Wednesday its exclusive commercial partner has launched its EarlyCDT Lung test in the US.
EarlyCDT Lung is a blood test for tumour-related antibodies specific to lung cancer. Biodesix Inc will market the test under its Notify Lung brand.
"This test partners with Biodesix's existing Notify XL2TM test which is designed to help identify lung nodules with a very low risk of cancer. Both tests will be offered together as the Nodify Lung Nodule Risk Assessment strategy, giving physicians the ability to order both tests from a single blood draw," Oncimmune said.
The strategic commercialisation agreement between the two firms was announced in late June. Under the terms of the agreement, Biodesix has acquired Oncimmune's CLIA laboratory facilities in Kansas for USD1.0 million.
Oncimmune granted Bidesix an option to commercialise EarlyCDT Lung as a screening diagnostic for cancer in the US. Overall, the commercialisation deal is worth up to USD28 million over five years to Oncimmune.
Speaking Wednesday, Oncimmune Chief Executive Adam Hill said: "Biodesix is a leader in lung cancer diagnostics and therefore is an excellent partner to unlock the potential of Early CDT Lung in the US, one of the largest addressable markets in the world.
"Since completing the strategic commercialisation agreement with Biodesix in November, they have exceeded our expectations and are fully motivated to deliver the full commercial potential of the product, now branded Nodify CDT in the US."
Shares in Oncimmune were 1.2% higher in London on Wednesday afternoon at 82.50 pence each.
By Paul McGowan; paulmcgowan@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
Oncimmune (ONC)